Last reviewed · How we verify

NCT00607802

Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer

Withdrawn NA Last updated 19 January 2017
What this trial tests

NA trial testing leukocyte therapy in Unspecified Adult Solid Tumor, Protocol Specific. Withdrawn.

Quick facts

Lead sponsorWake Forest University Health Sciences
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Primary purposetreatment

Drugs / interventions tested

Conditions studied

Sponsor

Wake Forest University Health Sciences

Who can join

Under 120, any sex, with Unspecified Adult Solid Tumor, Protocol Specific or Unspecified Childhood Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer. PURPOSE: This clinical trial is studying the side effects of donor white blood cell infusion in treating patients with metastatic or unresectable cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific

Currently open trials in the same condition.

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00607802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing